Cartesian Therapeutics (RNAC) Invested Capital: 2015-2025
Historic Invested Capital for Cartesian Therapeutics (RNAC) over the last 10 years, with Sep 2025 value amounting to -$35.8 million.
- Cartesian Therapeutics' Invested Capital fell 4866.49% to -$35.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$35.8 million, marking a year-over-year decrease of 4866.49%. This contributed to the annual value of -$6.8 million for FY2024, which is 98.35% up from last year.
- Latest data reveals that Cartesian Therapeutics reported Invested Capital of -$35.8 million as of Q3 2025, which was down 1,318.44% from -$2.5 million recorded in Q2 2025.
- Cartesian Therapeutics' 5-year Invested Capital high stood at $102.3 million for Q4 2022, and its period low was -$411.9 million during Q4 2023.
- For the 3-year period, Cartesian Therapeutics' Invested Capital averaged around -$43.2 million, with its median value being -$6.8 million (2024).
- Its Invested Capital has fluctuated over the past 5 years, first surged by 4,910.51% in 2022, then plummeted by 4,866.49% in 2025.
- Quarterly analysis of 5 years shows Cartesian Therapeutics' Invested Capital stood at $28.5 million in 2021, then skyrocketed by 259.19% to $102.3 million in 2022, then tumbled by 502.60% to -$411.9 million in 2023, then surged by 98.35% to -$6.8 million in 2024, then crashed by 4,866.49% to -$35.8 million in 2025.
- Its Invested Capital stands at -$35.8 million for Q3 2025, versus -$2.5 million for Q2 2025 and -$21.8 million for Q1 2025.